

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response... | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

| | | | | | | | | |
|--|---------|----------|--|--|--|--|--|--|
| 1. Name and Address of Reporting Person * Cosendai Gregoire | | | 2. Issuer Name and Ticker or Trading Symbol SECOND SIGHT MEDICAL PRODUCTS INC [EYES] | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ Director ____ 10% Owner <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) VP Clinical Affairs | | |
| (Last) 12744 SAN FERNANDO ROAD, SUITE 400 | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 01/04/2018 | | | | | |
| (Street) SYLMAR, CA 91342 | | | 4. If Amendment, Date Original Filed (Month/Day/Year) | | | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person ____ Form filed by More than One Reporting Person | | |
| (City) | (State) | (Zip) | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | | | | | | | | 23,484 (1) | D | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|---|-----|--|-----------------|---|--|--|--|--|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | | | | | |
| Non-Qualified Stock Option (right to buy) | \$ 2.06 | 01/04/2018 | | A | | 65,000 | | 01/04/2019(2) | 01/04/2028 | Common Stock | 65,000 (6) | 65,000 | D | |
| Warrant to Purchase Common Stock | \$ 1.47 | | | | | | | 03/14/2017 | 03/14/2022 | Common Stock | 3,366 | 3,366 | D | |
| Non-Qualified Stock Option (right to buy) | \$ 1.97 | | | | | | | 01/03/2018(3) | 01/03/2027 | Common Stock | 228,190 | 228,190 | D | |
| Non-Qualified Stock Option (right to buy) | \$ 4.10 | | | | | | | 01/21/2017(3) | 01/21/2026 | Common Stock | 11,513 | 11,513 | D | |
| Non-Qualified Stock Option (right to buy) | \$ 5 | | | | | | | 11/01/2009(4) | 11/01/2018 | Common Stock | 20,000 | 200,000 | D | |

| | | | | | | | | | | | | | | |
|---|----------|--|--|--|--|--|--|---------------------------|------------|--------------|--------|--|--------|---|
| Non-Qualified Stock Option (right to buy) | \$ 5 | | | | | | | 02/01/2010 ⁽⁴⁾ | 02/01/2019 | Common Stock | 5,081 | | 5,081 | D |
| Non-Qualified Stock Option (right to buy) | \$ 5 | | | | | | | 05/01/2010 ⁽⁴⁾ | 05/01/2019 | Common Stock | 10,000 | | 10,000 | D |
| Non-Qualified Stock Option (right to buy) | \$ 5 | | | | | | | 02/01/2011 ⁽⁴⁾ | 02/01/2020 | Common Stock | 14,475 | | 14,475 | D |
| Non-Qualified Stock Option (right to buy) | \$ 5 | | | | | | | 06/01/2011 ⁽⁴⁾ | 06/01/2020 | Common Stock | 2,125 | | 2,125 | D |
| Non-Qualified Stock Option (right to buy) | \$ 5 | | | | | | | 12/01/2011 ⁽⁵⁾ | 12/01/2020 | Common Stock | 25,000 | | 25,000 | D |
| Non-Qualified Stock Option (right to buy) | \$ 5 | | | | | | | 03/01/2012 ⁽⁵⁾ | 03/01/2021 | Common Stock | 6,650 | | 6,650 | D |
| Non-Qualified Stock Option (right to buy) | \$ 5 | | | | | | | 03/01/2013 ⁽⁵⁾ | 03/01/2022 | Common Stock | 7,750 | | 7,750 | D |
| Non-Qualified Stock Option (right to buy) | \$ 5 | | | | | | | 04/01/2015 ⁽⁵⁾ | 04/01/2024 | Common Stock | 10,937 | | 10,937 | D |
| Non-Qualified Stock Option (right to buy) | \$ 9 | | | | | | | 09/26/2015 ⁽⁵⁾ | 09/26/2024 | Common Stock | 51,009 | | 51,009 | D |
| Non-Qualified Stock Option (right to buy) | \$ 13.09 | | | | | | | 03/26/2016 ⁽⁵⁾ | 03/25/2025 | Common Stock | 6,250 | | 6,250 | D |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--------------------------------|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |

| | | | | |
|---|--|--|---------------------|--|
| Cosendai Gregoire 12744 SAN FERNANDO ROAD SUITE 400 SYLMAR, CA 91342 | | | VP Clinical Affairs | |
|---|--|--|---------------------|--|

Signatures

| | | |
|--|--|---------------------|
| Gregoire Cosendai | | 01/08/2018 |
| <small>**Signature of Reporting Person</small> | | <small>Date</small> |

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares acquired as part of scheduled ESPP purchases.
The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 4, 2018 (the "Vesting Commencement Date") and 6.25% of the total number of shares shall vest each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date.
- (2) Options vest over a four year term of which one-fourth vest on the Date Exercisable, with the remaining options vesting quarterly over three years thereafter.
- (3) Options vest in 5 yearly increments starting with the Date Exercisable
- (4) Options vest in 4 yearly increments starting with the Date Exercisable
- (5) Not Applicable
- (6) Not Applicable

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.